VINBLASTINE SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C46H58N4O9.H2O4S
Molecular Weight	909.053
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.[H][C@@]12N3CC[C@@]14C5=CC(=C(OC)C=C5N(C)[C@@]4([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]6(C[C@H]7CN(C[C@](O)(CC)C7)CCC8=C6NC9=C8C=CC=C9)C(=O)OC

InChI

InChIKey=KDQAABAKXDWYSZ-PNYVAJAMSA-N

InChI=1S/C46H58N4O9.H2O4S/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7;1-5(2,3)4/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3;(H2,1,2,3,4)/t28-,37-,38+,39+,42-,43+,44+,45-,46-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C46H58N4O9
Molecular Weight	810.9741
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24404355

Vinblastine is a Vinca alkaloid obtained from the Madagascar periwinkle plant. Vinca alkaloids were found out in the 1950's by Canadian scientists, Robert Noble and Charles Beer for the first time. Medicinal applications of this plant lead to the monitoring of these compounds for their hypoglycemic activity, which is of little importance compared to their cytotoxic effects. They have been used to treat diabetes, high blood pressure and the drugs have even been used as disinfectants. Nevertheless, the vinca alkaloids are so important for being cancer fighters. The mechanism of action of vinblastine sulfate has been related to the inhibition of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vinblastine is an antineoplastic agent used to treat Hodgkin's disease, non-Hodgkin's lymphomas, mycosis fungoides, cancer of the testis, Kaposi's sarcoma, Letterer-Siwe disease, as well as other cancers.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin 66 Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1260766 \| https://www.ncbi.nlm.nih.gov/pubmed/8534917 \| http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Inhibitor 8146

Conditions

Condition	Modality	Highest Phase	Product
Hodgkin's lymphoma 34 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8307	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 5.46652815E11
Non-Hodgkin's lymphoma 79 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8307	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 5.46566406E11
Mycosis fungoides 30 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8307	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 5.46652815E11
Carcinoma of the testis 2 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8307	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 5.46652815E11
Kaposi’s sarcoma 7 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8307	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 5.46652815E11
Letterer-Siwe disease (histiocytosis X) 2 Sources: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110	Primary	Approved 8307	VINBLASTINE SULFATE Approved Use Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi’s sarcoma Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active., Hodgkin's Disease Vinblastine sulfate has been shown to be one of the most effective single agents for the treatment of Hodgkin’s disease. Advanced Hodgkin’s disease has also been successfully treated with several multiple-drug regimens that included vinblastine sulfate. Patients who had relapses after treatment with the MOPP program— mechlorethamine hydrochloride (nitrogen mustard), vincristine sulfate, prednisone and procarbazine—have likewise responded to combination-drug therapy that included vinblastine sulfate. A protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced Hodgkin’s disease. Advanced testicular germinal-cell cancers (embryonal carcinoma, teratocarcinoma and choriocarcinoma) are sensitive to vinblastine sulfate alone, but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents. The effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin; this schedule permits more cells to be arrested during metaphase, the stage of the cell cycle in which bleomycin is active. Launch Date 5.46652815E11

T_1/2

Value	Dose	Analyte	Population
26.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7070351/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
16.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7070351/	14 mg single, intravenous dose: 14 mg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
31.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7070351/	7 mg single, intravenous dose: 7 mg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1173 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/889590/	0.2 mg/kg single, intravenous dose: 0.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	VINBLASTINE serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6873152/			VINBLASTINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6873152/			VINBLASTINE serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.3 mg/m2 1 times / day multiple, intravenous MTD Dose: 1.3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.3 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(10 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	unhealthy, 18-73 n = 6 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	DLT: Neutropenia, Ileus... Dose limiting toxicities: Neutropenia (grade 4, 16.7%) Ileus (grade 4, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727
2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	DLT: Neutropenia, Ileus... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Ileus (grade 4, 33.3%) Neutropenic fever (grade 4, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(4 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 4 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	DLT: Neutropenia, Fatigue... Dose limiting toxicities: Neutropenia (grade 4, 50%) Fatigue (grade 3, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
10 mg/m2 1 times / month multiple, intravenous MTD Dose: 10 mg/m2, 1 times / month Route: intravenous Route: multiple Dose: 10 mg/m2, 1 times / month Co-administed with:: cyclosporine, p.o(17 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	unhealthy, 31-70 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 31-70 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	DLT: Neutropenia, Sepsis... Dose limiting toxicities: Neutropenia (grade 4, 66.7%) Sepsis (grade 5, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254

AEs

AE	Significance	Dose	Population
Ileus	grade 4, 16.7% DLT	1.3 mg/m2 1 times / day multiple, intravenous MTD Dose: 1.3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.3 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(10 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	unhealthy, 18-73 n = 6 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727
Neutropenia	grade 4, 16.7% DLT	1.3 mg/m2 1 times / day multiple, intravenous MTD Dose: 1.3 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.3 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(10 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727	unhealthy, 18-73 n = 6 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4727
Ileus	grade 4, 33.3% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenia	grade 4, 33.3% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenic fever	grade 4, 33.3% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(5 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Fatigue	grade 3, 25% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(4 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 4 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenia	grade 4, 50% DLT	2.6 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 2.6 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.6 mg/m2, 1 times / day Co-administed with:: valspodar, i.v(4 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726	unhealthy, 18-73 n = 4 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 18-73 Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/15269145 Page: p.4726
Neutropenia	grade 4, 66.7% DLT	10 mg/m2 1 times / month multiple, intravenous MTD Dose: 10 mg/m2, 1 times / month Route: intravenous Route: multiple Dose: 10 mg/m2, 1 times / month Co-administed with:: cyclosporine, p.o(17 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	unhealthy, 31-70 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 31-70 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254
Sepsis	grade 5, 16.7% DLT, Disc. AE	10 mg/m2 1 times / month multiple, intravenous MTD Dose: 10 mg/m2, 1 times / month Route: intravenous Route: multiple Dose: 10 mg/m2, 1 times / month Co-administed with:: cyclosporine, p.o(17 mg/kg/d) Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254	unhealthy, 31-70 n = 3 Health Status: unhealthy Condition: Renal Cell Carcinoma Age Group: 31-70 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/7747714 Page: p.254

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inhibitor 1532 inducer 753	inhibitor 1695	inhibitor 1789

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2A6 670 CYP2C8 869 CYP2C19 1410 CYP2E1 846 MDR3 8 MRP1 106 MRP2 363 MRP3 156 MRP4 202 BSEP 392 BCRP 678 OATP1B1 770 OATP1B3 691 OATP2B1 121 OCT1 498	CYP3A 188 P-gp 1491 MDR3 3 MRP1 102 MRP2 196	P-gp 252 MRP1 47 MRP2 108 BCRP 74

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1620	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 702	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 929	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	no [IC50 >10 uM]
MRP3 206	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
BCRP 751	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/	no
MDR3 9	inhibitor 3185 Sources: https://transportal.compbio.ucsf.edu/compounds/vinblastine/	no
OATP2B1 124	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
OCT1 513	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	no
CYP2C8 923	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/26721703/	weak [IC50 100 uM]
MRP2 452	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00570 \| https://go.drugbank.com/articles/A15931 \| https://pubmed.ncbi.nlm.nih.gov/19421845/ \| https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 21 uM]
MRP1 170	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00570 \|https://pubmed.ncbi.nlm.nih.gov/8621644/ \| https://pubmed.ncbi.nlm.nih.gov/18457386/	yes [IC50 30 uM]
CYP3A4 1857	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00570 \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTU5In19	yes [IC50 32 uM]
MRP4 235	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 35.1 uM]
OATP1B3 700	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/ \| https://pubmed.ncbi.nlm.nih.gov/25618019/	yes [IC50 43.5 uM]
OATP1B1 785	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00570 \|https://pubmed.ncbi.nlm.nih.gov/21861202/ \| https://pubmed.ncbi.nlm.nih.gov/25618019/ \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1OSJ9fQ%3D%3D	yes [IC50 46.8 uM]
BSEP 393	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00570 \|https://go.drugbank.com/articles/A16121 \| https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 62 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/8258200/	yes [Ki 42 uM]
BCRP 751	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/31155684/	yes
MRP1 170	inducer 1515 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/12429346/	yes
MRP2 452	inducer 1515 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/15849751/	yes
P-gp 1588	inducer 1515 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/12429346/	yes
CYP3A4 1857	inducer 1515 Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/20959500/	yes	yes (co-administration study) Comment: Vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test). Sources: https://go.drugbank.com/drugs/DB00570 \| https://pubmed.ncbi.nlm.nih.gov/20959500/

Drug as victim

Target	Modality	Activity	Clinical evidence
MRP2 196	substrate 3264 Sources: https://go.drugbank.com/drugs/DB00570 \| https://transportal.compbio.ucsf.edu/compounds/vinblastine/	yes [Km 137.3 uM]
P-gp 1491	substrate 3264 Sources: https://go.drugbank.com/drugs/DB00570 \| https://go.drugbank.com/articles/A15815 \| https://transportal.compbio.ucsf.edu/compounds/vinblastine/	yes [Km 89.2 uM]
CYP3A4 1670	substrate 3264 Sources: https://go.drugbank.com/drugs/DB00570 \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C930&ns=ncit&type=relationship&key=932053897&b=1&n=0&vse=null	yes
MDR3 3	substrate 3264 Sources: https://transportal.compbio.ucsf.edu/compounds/vinblastine/ \| https://pubmed.ncbi.nlm.nih.gov/20190787/	yes
MRP1 102	substrate 3264 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.12889	yes
CYP3A 188	substrate 3264 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77&type=display	yes	yes (co-administration study) Comment: Enhanced toxicity has been reported in patients receiving concomitant erythromycin Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77&type=display

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA019FUD	https://www.aablocks.com/goods/Goods/detail?id=AA019FUD
AHH Chemical co.,ltd	NP-0159	http://www.ahhchemical.com/product/NP-0159.html
AK Scientific, Inc. (AKSCI)	Q943	http://www.aksci.com/item_detail.php?cat=Q943
Aaron Chemicals	AR019GM5	http://www.aaronchem.com/865-21-4
AbMole Bioscience	M4347	http://www.abmole.com/products/vinblastine.html
Achemtek	0102-014586	http://www.achemtek.com/865-21-4
Acorn PharmaTech	ACN-047385	http://www.acornpharmatech.com/
Alsachim	1117	http://www.alsachim.com/product-C3219-glo.bal-view.html
Ambinter	Amb22801678	http://www.ambinter.com/reference/22801678
ApexBio Technology	N2256	http://www.apexbt.com/vinblastine.html
Aurora Fine Chemicals LLC	A24.076.208	http://online.aurorafinechemicals.com/info?ID=A24.076.208
Aurora Fine Chemicals LLC	K16.667.094	http://online.aurorafinechemicals.com/info?ID=K16.667.094
Aurum Pharmatech LLC	W-5281	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5281
AvaChem Scientific	1012B	http://www.avachem.com/productSearch.asp?1012B
BOC Sciences	865-21-4	https://www.bocsci.com/vinblastine-cas-865-21-4-item-84-78578.html
BOC Sciences	15228-71-4	https://www.bocsci.com/vinrosidine-cas-15228-71-4-item-59529.html
BioCrick	BCN2376	http://www.biocrick.com/Vinblastine-BCN2376.html
BioSynth	Q-100868	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100868.html
Calbiochem	677175	http://www.emdbiosciences.com/product/677175
Chem Scene	CS-1336	http://www.chemscene.com/865-21-4.html
ChemFaces	CFN90230	http://www.chemfaces.com/natural/Vinblastine-CFN90230.html
ChemMol	30107940	http://www.chemmol.com/chemmol/30107940.html
ChemMol	49428962	http://www.chemmol.com/chemmol/49428962.html
ChemMol	99158126	http://www.chemmol.com/chemmol/99158126.html
Chemspace	CSSB00159262891	https://chem-space.com/CSSB00159262891
Chemspace	CSSB02125592927	https://chem-space.com/CSSB02125592927
Chemspace	CSSB02235353200	https://chem-space.com/CSSB02235353200
Clearsynth	CS-P-01207	https://www.clearsynth.com/en/CSP01207.html
DC Chemicals	DCC-002	http://www.dcchemicals.com//product_show-Vinblastine.html
Debye Scientific	DB-050310	http://www.debyesci.com/cas_865-21-4.html
EMD Millipore	677175	http://www.emdbiosciences.com/product/677175
Glentham Life Sciences	GP2901	http://www.glentham.com/products/product/GP2901/
Hairui	HR122895	http://www.hairuichem.com/en/product/865-21-4.html
Herbest Bio-Tech	HH231713	http://www.bjherbest.com/analytical-standard/alkaloids/vinblastine-865-21-4.html
Lab Network	LN01343210	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343210
Lab Network	LN03258097	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN03258097
MedChem Express	HY-17418	https://www.medchemexpress.com/Vinblastine.html
MolPort	MolPort-005-910-359	https://www.molport.com/shop/molecule-link/MolPort-005-910-359
MuseChem	I005196	https://www.musechem.com/product/I005196.html
OChem	12831	http://www.ocheminc.com/index.php?act=psearch&pid=865V214
Parchem	30287	http://www.parchem.com/chemical-supplier-distributor/Vinblastine-020287.aspx
Selleck Chemicals	S1248	http://www.selleckchem.com/products/Vinblastine.html
Smolecule	S568857	https://www.smolecule.com/products/s568857
Smolecule	S599355	https://www.smolecule.com/products/s599355
Smolecule	S616017	https://www.smolecule.com/products/s616017
Synchem UG and Co KG	67402	http://www.synchem.de/chemical_Vinblastine.html
THE BioTek	bt-302979	https://www.thebiotek.com/product/others/bt-302979
THE BioTek	bt-318822	https://www.thebiotek.com/product/others/bt-318822
THE BioTek	bt-333873	https://www.thebiotek.com/product/others/bt-333873
THE BioTek	bt-338291	https://www.thebiotek.com/product/others/bt-338291
THE BioTek	bt-345135	https://www.thebiotek.com/product/others/bt-345135
Vitas-M Laboratory	STL453006	http://www.request.vitasmlab.com/index.php?option=com_search_stk&Itemid=22&stk=STL453006&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Yuhao Chemical	XJ1373	http://www.chemyuhao.com/865-21-4.html
iChemical	EBD2185099	http://www.ichemical.com/products/865-21-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-7852064208	https://mcule.com/MCULE-7852064208/
mcule	MCULE-9967454324	https://mcule.com/MCULE-9967454324/

PubMed

Title	Date	PubMed
[High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer].	2002 Aug	12243071
5-fluorouracil-Induced cardiotoxicity.	2002 Jan-Feb	11999096
The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.	2002 Jun	12161935
[Results of organ-preserving therapy for invasive bladder cancer].	2002 May-Jun	12180056
Metastatic renal clear cell carcinoma mimicking stage IV lung cancer.	2003	14620276
NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21.	2003 Jan 1	12517776
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.	2003 Jan 27	12610498
Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy.	2003 Jan 3	12478072
Hepatic reticuloendothelial system dysfunction after ischemia-reperfusion: role of P-selectin-mediated neutrophil accumulation.	2003 Sep	12942455
[Clinical study of Hodgkin's disease after 25 years].	2004	15134038
Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation.	2004 Aug 2	15266324
The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia.	2004 Dec	15595999
Dynamic targeting of microtubules by TPPP/p25 affects cell survival.	2004 Dec 1	15564385
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.	2004 Feb 6	14627698
Development and characterization of an open tubular column containing immobilized P-glycoprotein for rapid on-line screening for P-glycoprotein substrates.	2004 Jan 25	14670744
Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.	2004 May	15568225
Tissue-specificity of apoptosis in hepatoma-derived cell lines.	2004 May	15258469
Anticancer agents are potent neurotoxins in vitro and in vivo.	2004 Sep	15349862
Development and characterization of an immobilized human organic cation transporter based liquid chromatographic stationary phase.	2005 Apr 25	15734168
Crystal structure of vinorine synthase, the first representative of the BAHD superfamily.	2005 Apr 8	15665331
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.	2005 Feb 14	15685237
[A case of an asynchronic triple tumorous disorder: a rectal adenocarcinoma, a carcinoma of the kidney and a prostatic adenocarcinoma--case report].	2005 Jan	15813456
[Comparison of TK gene mutation assay in TK6 and TK6-E6 cell induced by vinblastin and colcemid].	2006 Jul	16986510
Cytoskeletal architecture differentially controls post-transcriptional processing of IL-6 and IL-8 mRNA in airway epithelial-like cells.	2006 May 15	16499908
[Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life].	2007	18080983
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?	2007 Aug	17714996
Multi-disciplinary treatment of a rare pelvic cavity ependymoma.	2007 Aug 31	17722249
In silico prediction of pregnane X receptor activators by machine learning approaches.	2007 Jan	17003167
Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.	2007 Jun	17596674
HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.	2007 Mar 7	17343726
The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients.	2007 Oct	17824915
Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy.	2007 Sep 14	17854511
Mitigation of nociception via transganglionic degenerative atrophy: possible mechanism of vinpocetine-induced blockade of retrograde axoplasmic transport.	2008	18413267
Vinflunine in the treatment of bladder cancer.	2008 Dec	19337431
A review of topotecan in combination chemotherapy for advanced cervical cancer.	2008 Feb	18728710
Efficiency of propolis extract against mitochondrial stress induced by antineoplasic agents (doxorubicin and vinblastin) in rats.	2008 Feb	18335809
Subdural effusion in a CNS involvement of systemic juvenile xanthogranuloma: a case report treated with vinblastin.	2008 Feb	17720345
Wound healing in patients with cancer.	2008 Jan 11	18264518
A review on plant-derived natural products and their analogs with anti-tumor activity.	2008 Mar	21279166
Natural and synthetic polymers as inhibitors of drug efflux pumps.	2008 Mar	17896100
[Squamous cell carcinoma of the renal pelvis with elevation of G-CSF in the serum: a case report].	2008 Nov	19068728
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study.	2009 Aug 18	19623176
New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.	2009 Jul	22649602
Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein.	2009 May 15	19269968
Summary of the american college for advancement in medicine november 2007 conference on integrative medicine: advancing science and clinical practice.	2009 Sep	18955329
Long term outcome of adolescent and adult patients with pineal parenchymal tumors treated with fractionated radiotherapy between 1982 and 2003--a single institution's experience.	2010 Dec 26	21184689
A screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compounds.	2010 Jul 15	20657644
Cutaneous lesions of the nose.	2010 Jun 4	20525327
(2E,4E)-1-(6-Chloro-2-methyl-4-phenyl-3-quinol-yl)-5-phenyl-penta-2,4-dien-1-one.	2010 May 12	21579414
Factors influencing overall survival rates for patients with pineocytoma.	2010 Nov	20461445

Patents

Sample Use Guides

In Vivo Use Guide

It is wise to initiate therapy for adults by administering a single intravenous dose of 3.7 mg/m2 of body surface area (bsa). Thereafter, white-blood-cell counts should be made to determine the patient’s sensitivity to vinblastine sulfate. A simplified and conservative incremental approach to dosage at weekly intervals for adults may be outlined as follows: First dose ........................... 3.7 mg/m2 bsa Second dose ........................... 5.5 mg/m2 bsa Third dose ........................... 7.4 mg/m2 bsa Fourth dose ........................... 9.25 mg/m2 bsa Fifth dose ........................... 11.1 mg/m2 bsa The above-mentioned increases may be used until a maximum dose not exceeding 18.5 mg/m2 bsa for adults is reached. The dose should not be increased after that dose which reduces the white-cell count to approximately 3000 cells/mm3 . In some adults, 3.7 mg/m2 bsa may produce this leukopenia; other adults may require more than 11.1 mg/m2 bsa; and, very rarely, as much as 18.5 mg/m2 bsa may be necessary. For most adult patients, however, the weekly dosage will prove to be 5.5 to 7.4 mg/m2 bsa. When the dose of vinblastine sulfate which will produce the above degree of leukopenia has been established, a dose of 1 increment smaller than this should be administered at weekly intervals for maintenance. Thus, the patient is receiving the maximum dose that does not cause leukopenia. It should be emphasized that, even though 7 days have elapsed, the next dose of vinblastine sulfate should not be given until the white-cell count has returned to at least 4000/mm3. In some cases, oncolytic activity may be encountered before leukopenic effect. When this occurs, there is no need to increase the size of the subsequent doses

Route of Administration: Intravenous

In Vitro Use Guide

15 nM vinblastine inhibit CHO cell proliferation

Substance Class	Chemical Created by `admin` on `Fri Dec 16 15:52:34 UTC 2022` Edited by `admin` on `Fri Dec 16 15:52:34 UTC 2022`
Record UNII	N00W22YO2B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VINBLASTINE SULFATE

Official Name

English

NSC-49842

Code

English

VINBLASTINE SULFATE [USP-RS]

Common Name

English

29060LE

Code

English

VINBLASTINE SULFATE [MART.]

Common Name

English

ALKABAN-AQ

Common Name

English

VLB MONOSULFATE

Common Name

English

VINBLASTINE SULFATE [IARC]

Common Name

English

29060-LE

Code

English

VINBLASTINE SULPHATE

Common Name

English

VINBLASTINE SULFATE [USP MONOGRAPH]

Common Name

English

VINCALEUKOBLASTINE, SULFATE (1:1) (SALT)

Common Name

English

VINBLASTINE SULFATE [WHO-IP]

Common Name

English

VINBLASTINE SULFATE [ORANGE BOOK]

Common Name

English

Vinblastine sulfate [WHO-DD]

Common Name

English

VINBLASTINE SULFATE [MI]

Common Name

English

VELBAN

Brand Name

English

VINBLASTINI SULFAS [WHO-IP LATIN]

Common Name

English

VINCALEUKOBLASTINE SULFATE

Common Name

English

VINBLASTINE SULFATE [EP MONOGRAPH]

Common Name

English

VINBLASTINE SULFATE [USAN]

Common Name

English

VINBLASTINE SULFATE [JAN]

Common Name

English

VINBLASTINE SULFATE [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67422